TRY NOW

Enhance and accelerate your early stage research with trusted and comprehensive intelligence from Thomson Reuters.

Start your free trial in just two simple steps.

Get your FREE trial

Enrich your discovery science with market leading, manually curated scientific intelligence. Systems Biology, Preclinical, Biomarkers, Chemistry, Biology, and Pharmacology - and everything in between. Covered from the perspective that matters most – yours.
Customer Feedback
Customer Feedback

Annette Bakker, Chief Scientific Officer from CTF, explains the reasons why she likes to work with Thomson Reuters. Currently using MetaCore™ to identify disease treatment options.

Live & Recorded Training

Attend one of our regularly scheduled webinar training sessions for overviews of features, tools, and content – find the schedule here

Free Pathway Maps

Search or browse through a wide range of proprietary multi-step canonical pathway maps here.

Featured News

The latest news from Life Sciences Research
The future of COPD treatment

The future of COPD treatment

Our research shows greater focus on preventative therapies

Translational Medicine

Translational Medicine

Supplement-Size Doses of Antioxidants Hasten Lung Cancer Progression

Tet Proteins Erase Epigenetic Marks

Tet Proteins Erase Epigenetic Marks

It is (reasonably) common knowledge that DNA is written in a simple four-letter code: ACTG. Too simple, actually.

Blog Highlights

Read our latest blog posts

FDA Approval of Dual Balloon System could Reshape Weight Loss Options

The market for weight loss devices has seen a flurry of recent activity, most recently with the FDA approval of an intragastric dual balloon system ...

Quanta Seeks to Bring Center-Quality Hemodialysis to In-Home Delivery after one of Europe’s Largest Med-tech Fund-Raisings Ever

Formerly a venture investor and a director of Quanta Fluid Solutions (Alcester, UK), John Milad rolled up his sleeves, becoming the company’s CEO in January ...

Eli Lilly & Co’s Solanezumab: A New Analysis Highlights Early Evidence of Alzheimer’s Disease Modification

New evidence released in late July 2015 shows that Eli Lilly & Co’s anti-amyloid agent solanezumab (LY-2062430) is the first drug to slow the progression ...

Whitepapers & Publications

View our recent whitepapers and publications

Biomarkers: An indispensible addition to the drug development toolkit

In this white paper, Thomson Reuters explores the role of biomarkers as evaluative tools in improving clinical research and the ...

THE YEAR'S NEW DRUGS & BIOLOGICS, 2013: PART I

http://dx.doi.org/10.1358/dot.2014.50.1.2116673

Latest on Twitter

Latest on Linked In